Serva Energy Information

Serva is a nuclear technology company developing a new production pathway for Actinium-225 (Ac-225), a radioisotope of growing interest in targeted radiopharmaceutical therapy. As radiopharmaceutical development advances, reliable access to specialized therapeutic isotopes remains a critical industry challenge. Serva is focused on addressing that need through an alternative approach to Ac-225 production. Building on expertise in nuclear materials science and reactor technology, Serva is developing proprietary process technology that applies irradiation using existing nuclear power reactor infrastructure. This approach is intended to create an additional pathway for future Ac-225 supply. Our work brings together scientific expertise, engineering, and a practical understanding of the infrastructure required for isotope production. Our long-term objective is to help strengthen Ac-225 supply to support the continued development of targeted radiopharmaceutical therapies. Learn more about our approach and the team behind it.